Difficult asthma can often be well controlled
|
Tweet
|
|
Most people with uncontrolled asthma can achieve good control over their disease using a combination of the inhaled steroid fluticasone and the long-acting beta-2-agonist salmeterol, according to a study supported by GlaxoSmithKline R&D Limited.
Glaxo produces the combination product used in the study, marketed as Advair or Seretide.
"This approach should be the preferred treatment selection for patients whose asthma is uncontrolled, regardless of their previous inhaled corticosteroid regimen,” Dr. Eric D. Bateman from the University of Cape Town in South Africa and an international team conclude in the report, which is published in the American Journal of Respiratory and Critical Care Medicine.
Some 3,400 patients with uncontrolled asthma were randomly assigned to fluticasone alone or the combination of fluticasone and salmeterol for one year.
Overall, significantly more patients achieved control with fluticasone/salmeterol than with fluticasone alone. In addition, asthma control was achieved more rapidly and at a lower corticosteroid dose with the salmeterol/fluticasone combination than with fluticasone alone.
Total control of asthma, defined as the complete absence of all features of asthma for at least 7 of 8 weeks, was achieved by 41 percent of those using salmeterol/fluticasone versus 28 percent of those using only fluticasone, after one year.
“Well-controlled” asthma was achieved by 71 percent of previously untreated subjects on salmeterol/fluticasone versus 65 percent of like subjects on fluticasone alone. The percentages were slightly lower for participants who had been treated with steroids previously.
These results suggest that total control of asthma “should be the aim of treatment for all asthma patients,” Bateman and colleagues charge.
In an editorial, Dr. Neil C. Barnes from the UK’s London Chest Hospital worries that the “high compliance achieved in the study may be irreproducible in practice.” More research will be required to “bridge the gap between what can be achieved in a trial and what occurs in practice,” he writes.
SOURCE: American Journal of Respiratory and Critical Care Medicine, October 15, 2004.
Revision date: July 6, 2011
Last revised: by Jorge P. Ribeiro, MD
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Child addicts at heart of Indonesia anti-smoking suit
- Full Story - - »»»
Miracle sweetener stevia may have a sour note
- Full Story - - »»»
Scientists turn skin cells into beating heart muscle
- Full Story - - »»»
Too many people get angioplasties, study suggests
- Full Story - - »»»
Viewers’ family background affects how they react to MTV shows ‘16 and Pregnant,’ ‘Teen Mom’
- Full Story - - »»»
Weight management in pregnancy with diet is beneficial and safe and can reduce complications
- Full Story - - »»»

